• 1
    Sutherland L, Macdonald JK. Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis. Cochrane Database Syst Rev 2006; 2: 116.
  • 2
    Sutherland L, Macdonald JK. Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis. Cochrane Database Syst Rev 2006; 2: 125.
  • 3
    Eaden J, Abrams K, Ekbom A, et al. Colorectal cancer prevention in ulcerative colitis: a case-control study. Aliment Pharmacol Ther 2000; 14: 14553.
  • 4
    Velayos FS, Terdiman JP, Walsh JM. Effect of 5-aminosalicylate use on colorectal cancer and dysplasia risk: a systematic review and meta-analysis of observational studies. Am J Gastroenterol 2005; 100: 134553.
    Direct Link:
  • 5
    Vaur L, Vaisse B, Genes N, et al. Use of electronic pill boxes to assess risk of poor treatment compliance: results of a large-scale trial. Am J Hypertens 1999; 12: 37480.
  • 6
    Caro JJ, Salas M, Speckman JL, et al. Persistence with treatment for hypertension in actual practice. CMAJ 1999; 160: 645.
  • 7
    Evans JM, Newton RW, Ruta DA, et al. Frequency of blood glucose monitoring in relation to glycaemic control: observational study with diabetes database. BMJ 1999; 319: 836.
  • 8
    Kane SV, Cohen RD, Aikens JE, Hanauer SB. Prevalence of non-adherence with maintenance mesalamine in quiescent ulcerative colitis. Am J Gastroenterol 2001; 96: 292933.
    Direct Link:
  • 9
    Sninsky CA, Cort DH, Shanahan F, et al. Oral mesalamine (Asacol) for mildly to moderately active ulcerative colitis. A multicenter study. Ann Intern Med 1991; 115: 3505.
  • 10
    Kane SV. Systematic review: adherence issues in the treatment of ulcerative colitis. Aliment Pharmacol Ther 2006; 23: 57785.
  • 11
    Rubin G, Hungin AP, Chinn D, et al. Long-term aminosalicylate therapy is under-used in patients with ulcerative colitis: a cross-sectional survey. Aliment Pharmacol Ther 2002; 16: 188993.
  • 12
    Bernal I, Domènech E, Garcia-Planella E, et al. Medication-taking behaviour in a cohort of patients with inflammatory bowel disease. Dig Dis Sci 2006; 51: 21659.
  • 13
    López-San Román, Bermejo F, Carrera E, et al. Adherence to treatment in inflammatory bowel disease. Rev Esp Enferm Dig 2005; 97: 24957.
  • 14
    Shale MJ, Riley SA. Studies of compliance with delayed-release mesalazine therapy in patients with inflammatory bowel disease. Aliment Pharmacol Ther 2003; 18: 1918.
  • 15
    Beardon PH, McGilchrist MM, McKendrick AD, et al. Primary non-compliance with prescribed medication in primary care. BMJ 1993; 307: 8468.
  • 16
    Robinson A. Patient-reported compliance with 5-ASA drugs in inflammatory bowel disease: a multi-national study. Gastroenterology 2002; 122: A-499.
  • 17
    Shaw IS, Jobson BA, Silverman D. Is your patient taking the medicine? A simple assay to measure compliance with 5-aminosalicylic acid-containing compounds. Aliment Pharmacol Ther 2002; 16: 20539.
  • 18
    Kane S, Huo D, Aikens J, et al. Medication non-adherence and outcomes of patients with quiescent ulcerative colitis. Am J Med 2003; 114: 3943.
  • 19
    Hjortswang H, Jarnerot G, Curman B, et al. The influence of demographic and disease-related factors on health-related quality of life in patients with ulcerative colitis. Eur J Gastroenterol Hepatol 2003; 15: 101120.
  • 20
    Brentnall TA. Molecular underpinnings of cancer in ulcerative colitis. Curr Opin Gastroenterol 2003; 19: 648.
  • 21
    Van Staa TP, Card T, Logan RF, et al. Aminosalicylate use and colorectal cancer risk in inflammatory bowel disease: a large epidemiological study. Gut 2005; 54: 15738.
  • 22
    Moody GA, Jayanthi V, Probert CS, et al. Long-term therapy with sulphasalazine protects against colorectal cancer in ulcerative colitis: a retrospective study of colorectal cancer risk and compliance with treatment in Leicestershire. Eur J Gastroenterol Hepatol 1996; 8: 117983.
  • 23
    Bassi A, Dodd S, Williamson P, et al. Cost of illness of inflammatory bowel disease in the UK: a single centre retrospective study. Gut 2004; 53: 14718.
  • 24
    García Rodríguez LA, González-Pérez A, Johansson S, et al. Risk factors for inflammatory bowel disease in the general population. Aliment Pharmacol Ther 2005; 22: 30915.
  • 25
    Hobden A. Strategies to promote concordance within consultations. Br J Community Nurs 2006; 11: 2869.
  • 26
    Levy RL, Feld AD. Increasing patient adherence to gastroenterology treatment and prevention regimens. Am J Gastroenterol 1999; 94: 173342.
    Direct Link:
  • 27
    Sewitch MA, Abrahamowicz M, Barkun A, et al. Patient non-adherence to medication in inflammatory bowel disease. Am J Gastroenterol 2003; 98: 153544.
    Direct Link:
  • 28
    D’Inca R, Bertomoro P, Mazzocco K, et al. Risk factors for non-adherence to medication in inflammatory bowel disease patients. Aliment Pharmacol Ther 2008; 27: 16672.
  • 29
    Cervený P, Bortlík M, Kubena A, et al. Nonadherence in inflammatory bowel disease: results of factor analysis. Inflamm Bowel Dis 2007; 13: 12449.
  • 30
    Schneider J, Kaplan SH, Greenfield S, et al. Better physician-patient relationships are associated with higher reported adherence to antiviral therapy in patients with HIV infection. J Gen Intern Med 2004; 19: 1096103.
  • 31
    Beach MC, Keruly J, Moore RD. Is the quality of the patient-provider relationship associated with better adherence and health outcomes for patients with HIV. J Gen Intern Med 2006; 21: 6615.
  • 32
    Wroth TH, Pathman DE. Primary medication adherence in a rural population: the role of the patient-physician relationship and satisfaction with care. J Am Board Fam Med 2006; 19: 47886.
  • 33
    Bass MJ, Buck C, Turner L, et al. The physician’s actions and the outcome of illness in family practice. J Fam Pract 1986; 23: 437.
  • 34
    Rost K, Carter W, Inui T. Introduction of information during the initial medical visit: consequences for patient follow-through with physician recommendations for medication. Soc Sci Med 1989; 28: 31521.
  • 35
    Kerse N, Buetow S, Mainous AG, et al. Physician-patient relationship and medication compliance: a primary care investigation. Ann Fam Med 2004; 2: 45561.
  • 36
    Drossman DA. Psychosocial sound bites: exercises in the patient-physician relationship. Am J Gastroenterol 1997; 92: 141823.
  • 37
    Cecil WD, Killeen J. Control, compliance, and satisfaction in the family practice encounter. Fam Med 1997; 29: 6537.
  • 38
    Donovan JL, Blake DR. Patient non-compliance: deviance or reasoned decision-making. Soc Sci Med 1992; 34: 50713.
  • 39
    Veazie PJ, Cai S. A connection between medication adherence, patient sense of uniqueness, and the personalization of information. Med Hypotheses 2007; 68: 33542.
  • 40
    Horne R, Weinman J. Patients’ beliefs about prescribed medicines and their role in adherence to treatment in chronic physical illness. J Psychosom Res 1999; 47: 55567.
  • 41
    Hall NJ, Rubin GP, Dougall A, et al. The fight for ‘health-related normality’: a qualitative study of the experiences of individuals living with established inflammatory bowel disease (IBD). J Health Psychol 2005; 10: 44355.
  • 42
    Hall NJ, Rubin GP, Hungin AP, Dougall A. Medication beliefs among patients with inflammatory bowel disease who report low quality of life: a qualitative study. BMC Gastroenterol 2007; 7: 20.
  • 43
    Stockwell Morris L, Schulz RM. Patient compliance – an overview. J Clin Pharm Ther 1992; 17: 28395.
  • 44
    Kripalani S, Yao X, Haynes B. Interventions to enhance medication adherence in chronic medical conditions: a systematic review. Arch Intern Med 2007; 167: 5409.
  • 45
    Abbott SA. The benefits of patient education. Gastroenterol Nurs 1998; 21: 2079.
  • 46
    Rowlinson A. Inflammatory bowel disease 3: importance of partnership in care. Br J Nurs 1999; 8: 10138.
  • 47
    Krueger KP, Felkey BG, Berger BA. Improving adherence and persistence: a review and assessment of interventions and description of steps toward a national adherence initiative. Am J Pharm Assoc (Wash) 2003; 43: 66878.
  • 48
    Robinson GL, Gilbertson AD, Litwack L. The effects of a psychiatric patient education to medication program on post discharge compliance. Psychiatric Q 1987; 58: 1138.
  • 49
    Waters BM, Jensen L, Fedorak R. Effects of formal education for patients with inflammatory bowel disease: a randomized controlled trial. Can J Gastroenterol 2005; 19: 23544.
  • 50
    Robinson A, Thompson DG, Wilkin D, et al. Guided self-management and patient-directed follow-up of ulcerative colitis: a randomised trial. Lancet 2001; 358: 97681.
  • 51
    Kennedy AP, Nelson E, Reeves D, et al. A randomised controlled trial to assess the effectiveness and cost pf a patient orientated self management approach to chronic inflammatory bowel disease. Gut 2004; 53: 163945.
  • 52
    Richardson G, Sculpher M, Kennedy A, et al. Is self-care a cost effective use of resources? Evidence from a randomised trial in inflammatory bowel disease J Health Serv Res Policy 2006; 11: 22530.
  • 53
    Robinson A. Review article: inflammatory bowel disease – empowering the patient and improving outcomes. Aliment Pharmacol Ther 2004; 20(Suppl. 4): 847.
  • 54
    Epstein LH, Cluss PA. A behavioural medicine perspective on adherence to long-term medical regimens. J Consult Clin Psychol 1982; 50: 95071.
  • 55
    Claxton AJ, Cramer J, Pierce C. A systematic review of the associations between dose regimens and medication compliance. Clin Ther 2001; 23: 1296310.
  • 56
    Eisen SA, Miller DK, Woodward RS, et al. The effect of prescribed daily dose frequency on patient medication compliance. Arch Int Med 1990; 150: 18814.
  • 57
    Greenberg RN. Overview of patient compliance with medication dosing: a literature review. Clin Ther 1984; 6: 5929.
  • 58
    Dignass A, Veerman H. Once versus twice daily mesalazine (Pentasa) granules for the maintenance of remission in ulcerative colitis: results from a multinational randomised controlled trial. Gut 2008; 57(Suppl. 1): A1.
  • 59
    Petrilla AA, Benner JS, Battleman DS, et al. Evidence-based interventions to improve patient compliance with antihypertensive and lipid-lowering medications. Int J Clin Pract 2005; 59: 144151.
  • 60
    Simkins CV, Wenzloff NJ. Evaluation of a computerised reminder system in the enhancement of patient medication refill compliance. Drug Intell Clin Pharm 1986; 20: 799802.